Edesa Biotech, Inc. (EDSA)Healthcare | Biotechnology | Markham, Canada | NasdaqCM
5.93 USD
+0.79
(15.370%)
⇧
(April 17, 2026, 4 p.m.
EDT)
After hours: 5.93 Short-term: ★★☆☆☆ | Long-term: ★☆☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 11, 2026, 2:44 p.m. EDT
EDSA is a highly volatile biotech stock with a significant drop from its 52-week high of $9.37 to the current price of $5.52. The recent price history shows a downward trend with fluctuations, and the stock has a negative forward P/E and negative earnings, indicating poor financial performance. The positive news headlines suggest potential for growth due to Phase 3 trial results, but the lack of dividends and the negative financial metrics suggest caution. The short-term momentum appears weak, and the long-term fundamentals are not promising. Investors should be cautious and consider the risks associated with this stock. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.828919 |
| AutoETS | 0.828920 |
| MSTL | 0.834585 |
| AutoTheta | 0.926806 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 39% |
| H-stat | 39.00 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.046 |
| Excess Kurtosis | -1.81 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Market Cap | 52,692,312 |
| Forward P/E | -3.07 |
| Beta | -0.68 |
| Website | https://www.edesabiotech.com |
| Attribute | Value |
|---|---|
| 52 Week Change | 1.4915967 |
| Address1 | 100 Spy Court |
| All Time High | 6,938.4 |
| All Time Low | 0.72 |
| Ask | 6.06 |
| Ask Size | 1 |
| Average Daily Volume10 Day | 222,630 |
| Average Daily Volume3 Month | 4,332,309 |
| Average Volume | 4,332,309 |
| Average Volume10Days | 222,630 |
| Beta | -0.683 |
| Bid | 5.84 |
| Bid Size | 1 |
| Book Value | 0.559 |
| City | Markham |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | Canada |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 5.93 |
| Current Ratio | 16.818 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 5.97 |
| Day Low | 5.18 |
| Display Name | Edesa Biotech |
| Dividend Date | 1,560,124,800 |
| Earnings Timestamp End | 1,754,913,600 |
| Earnings Timestamp Start | 1,754,564,340 |
| Ebitda | -8,252,636 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -5.665 |
| Enterprise Value | 46,750,440 |
| Eps Forward | -1.93 |
| Eps Trailing Twelve Months | -1.07 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 4.3856 |
| Fifty Day Average Change | 1.5443997 |
| Fifty Day Average Change Percent | 0.35215244 |
| Fifty Two Week Change Percent | 149.15967 |
| Fifty Two Week High | 9.37 |
| Fifty Two Week High Change | -3.44 |
| Fifty Two Week High Change Percent | -0.36712915 |
| Fifty Two Week Low | 0.72 |
| Fifty Two Week Low Change | 5.21 |
| Fifty Two Week Low Change Percent | 7.2361107 |
| Fifty Two Week Range | 0.72 - 9.37 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,277,127,000,000 |
| Float Shares | 3,475,423 |
| Forward Eps | -1.93 |
| Forward P E | -3.0725389 |
| Free Cashflow | -5,372,837 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 17 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.13577 |
| Held Percent Institutions | 0.49021998 |
| Implied Shares Outstanding | 8,885,719 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,759,190,400 |
| Last Split Date | 1,696,982,400 |
| Last Split Factor | 1:7 |
| Long Business Summary | Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. It develops EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 3 clinical study to treat chronic allergic contact dermatitis. The company develops EB07, a monoclonal antibody, which is in a Phase 2 clinical study for the treatment of pulmonary fibrosis; and EB06, a human monoclonal antibody candidate that binds to chemokine ligand 10 (CXCL10) and inhibits the interaction of CXCL10 with its receptors, CXCR3A, and CXCR3B. It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. The company was founded in 2015 and is headquartered in Markham, Canada. |
| Long Name | Edesa Biotech, Inc. |
| Market | us_market |
| Market Cap | 52,692,312 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_313039720 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -7,815,939 |
| Next Fiscal Year End | 1,790,726,400 |
| Non Diluted Market Cap | 52,870,028 |
| Number Of Analyst Opinions | 3 |
| Open | 5.23 |
| Operating Cashflow | -7,892,393 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 289 800 9600 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 5.93 |
| Post Market Time | 1,776,469,749 |
| Previous Close | 5.14 |
| Price Hint | 2 |
| Price To Book | 10.608229 |
| Profit Margins | 0.0 |
| Quick Ratio | 16.508 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.79 |
| Regular Market Change Percent | 15.3696 |
| Regular Market Day High | 5.97 |
| Regular Market Day Low | 5.18 |
| Regular Market Day Range | 5.18 - 5.97 |
| Regular Market Open | 5.23 |
| Regular Market Previous Close | 5.14 |
| Regular Market Price | 5.93 |
| Regular Market Time | 1,776,456,001 |
| Regular Market Volume | 257,897 |
| Return On Assets | -0.55327 |
| Return On Equity | -0.96385 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 8,885,719 |
| Shares Percent Shares Out | 0.044699997 |
| Shares Short | 396,830 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 1,411,103 |
| Short Name | Edesa Biotech, Inc. |
| Short Percent Of Float | 0.048499998 |
| Short Ratio | 0.09 |
| Source Interval | 15 |
| State | ON |
| Symbol | EDSA |
| Target High Price | 19.0 |
| Target Low Price | 5.0 |
| Target Mean Price | 11.0 |
| Target Median Price | 9.0 |
| Total Cash | 12,051,748 |
| Total Cash Per Share | 1.444 |
| Total Debt | 0 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.07 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 2.61365 |
| Two Hundred Day Average Change | 3.3163497 |
| Two Hundred Day Average Change Percent | 1.2688576 |
| Type Disp | Equity |
| Volume | 257,897 |
| Website | https://www.edesabiotech.com |
| Zip | L3R 5H6 |